RDIF brings together the best Russian and international technologies in the fight against COVID-19

Production of antiviral drugs

RDIF and the ChemRar Group have launched the production of Avifavir - the first drug registered in Russia that has demonstrated effectiveness against COVID-19 in clinical trials.

Avifavir is one of the two registered COVID-19 drugs in the world and the first Favipiravir-based drug in the world approved for treatment of COVID-19.

More

Production of diagnostic tests for the detection of coronavirus

Jointly with Japan’s K.K. Mirai Genomics, RDIF has invested in the production and distribution of the Russian-Japanese diagnostic system EMG - Evotech-Mirai Genomics, which is one of the world’s most accurate and fastest systems for the detection of coronavirus. Results are achieved in just 30 minutes. The Japan Bank for International Cooperation has joined the project through the Russia-Japan Investment Fund.

More

Diagnosis and detection of pneumonia

RDIF has launched a project to diagnose and detect pneumonia, including that caused by coronavirus, using CT scans combined with the Russian- UAE artificial intelligence (AI) technology developed jointly by Group 42 (G42), RDIF and Medscan Group.

More

Production of the first Russian vaccine against coronavirus infection

RDIF and the R-Pharm Group have agreed to create a joint venture (JV) to produce the first Russian vaccine against coronavirus infection.
As part of the joint venture, a modern biotechnological production facility will be constructed in Yaroslavl to manufacture active pharmaceutical ingredients and finished dosage forms. There will also be potential to export products to the Middle East and other countries in the future.

More

Organization of a production site for a large-scale vaccine production

RDIF, Sistema and the Gamaleya National Research Institute of Epidemiology and Microbiology have agreed to cooperate to organise a production site at the Alium plant in Zelenograd in the Moscow region, for the large-scale production of the first vaccine for the prevention of coronavirus infection in Russia.

More

Production of a drug for coronavirus therapy based on blood plasma

RDIF and Rostec partner announced a partnership with Nacimbio (part of the State Corporation Rostec) to carry out a joint project for the production of a drug for coronavirus therapy based on blood plasma. One of Nacimbio’s enterprises has developed a universal technology for the production of human immunoglobulins for intravenous administration. The BioGam drug produced using this technology has successfully passed the first phase of clinical trials. The partnership involves the production of an immunoglobulin preparation containing antibodies to the SARS CoV-2 coronavirus.

More
RDIF has facilitated the exchange of humanitarian aid between Russia and the United States to combat coronavirus More
RDIF was one of the initiators of the Alliance against coronavirus More
RDIF, Rossiya Segodnya and Sechenov University publish a unique COVID-19 prevention and treatment handbook More
RDIF, Channel One and Vision Media Center organize "To our doctors. We Thank You!", a concert in support of doctors featuring Russian music stars More
RDIF supports online marathon Doctor Jazz Party More